David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and how it may continue to be applied – by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
23 July 2025 Important cases on discretionary denials, prosecution laches, and trade secrets have been heard at the appellate court over June and July, explain Nathan Mammen and Cole Tipton of Snell & Wilmer.